PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia

13 March 2024 -- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ( " PureTech " or the " Company " ), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials